MedTrace Logo

Rifaximin in Patients With Monoclonal Gammopathy

NCT03820817 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-04-20

No results posted yet for this study

Summary

This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.

Conditions

  • IgA Monoclonal Gammopathy
  • IgG Monoclonal Gammopathy
  • IgM Monoclonal Gammopathy
  • Light Chain Deposition Disease
  • Monoclonal Gammopathy
  • Smoldering Waldenstrom Macroglobulinemia
  • Waldenstrom Macroglobulinemia
  • Gammopathy, Monoclonal
  • Gammopathy Igg

Interventions

DRUG

Rifaximin

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Emory University

    lead OTHER

Principal Investigators

  • Ajay Nooka, MD · Emory University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2025-11-30
Completion
2025-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03820817 on ClinicalTrials.gov